Citi analyst Yigal Nochomovitz says his 100-physician survey of U.S. oncologists supports his "long-standing bull thesis" that Puma Biotechnology's Nerlynx is positioned to be a billion-dollar drug. Continued fundamental upside to the launch should limit investor concerns around a "stalled" launch that has been pressuring the stock, Nochomovitz tells investors in a research note. The survey indicates that one-in-four adjuvant Herceptin patients are expected to receive Nerlynx. This provides "substantive validation" that 20%-25% of Herceptin completers are high-risk and thus likely Nerlynx patients, Nochomovitz contends. The analyst lowered his price target for Puma shares to $151 from $164 and keeps a Buy rating on the name.